ClinicalTrials.gov (NCT01581060) Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours. U.S. National Institutes of Health.
Ref 544302
MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27.
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.